274
Participants
Start Date
June 26, 2021
Primary Completion Date
August 26, 2022
Study Completion Date
November 14, 2022
XC221
Participants will receive XC221 100 mg 2 times a day during 14 full days
Placebo
Participants will receive Placebo 2 times a day during 14 full days
"State Budgetary Institution of Healthcare of Moscow City Polyclinic No. 2 of the Moscow Department of Healthcare", Moscow
"Federal Budgetary Institution of Science Moscow Research Institute of Epidemiology and Microbiology named after G.N. Gabrichevsky of the Federal Service for the Oversight of Consumer Protection and Welfare", Moscow
"Regional Budgetary Institution of Healthcare Ivanovskaya Clinical Hospital named after Kuvaevykh", Ivanovo
"Limited Liability Company Medical Center Capital-Policy", Saint Petersburg
"Limited Liability Company Research Center Eco-Safety", Saint Petersburg
"LLC Sphere-Med", Saint Petersburg
"Saint Petersburg State Budgetary Institution of Healthcare City Pokrovskaya Hospital (4th Cardiology Department)", Saint Petersburg
"Saint Petersburg State Budgetary Institution of Healthcare City Polyclinic No. 4", Saint Petersburg
"Municipal Budgetary Institution of Healthcare Central City Hospital of Novoshakhtinsk", Novoshakhtinsk
"LLC Family Clinic", Yekaterinburg
"Regional State Budgetary Institution of Healthcare Medical-Sanitary Unit No. 2", Tomsk
RSV Therapeutics LLC
INDUSTRY